Hormonal
Type 2 diabetes should be managed as a component of Metabolic Dysfunction Syndrome (MDS) rather than solely as a hyperglycemic disorder, requiring holistic protection of target organs against all MDS-related metabolic disorders.
Do not treat Type 2 Diabetes as just a 'blood sugar problem.' Your risk of organ damage comes from the combination of high blood sugar, high blood pressure, high lipids, and excess weight. Effective management requires addressing all these metabolic factors together to protect your heart, kidneys, and eyes, rather than focusing on glucose alone.
T2D is just one component of MDS... It is more appropriate to call 'diabetic complications' as 'MDS-related target organ damage (TOD)', since their development involves not only hyperglycemia but also other metabolic disorders of MDS, promoting an up-to-date management philosophy.
Why this rating
This is a review article summarizing established pathophysiology and proposing a management framework; it cites numerous primary studies.
Source
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu et al. · Signal Transduction and Targeted Therapy · 2024
DOI 10.1038/s41392-024-01951-9
More from this paper
- Obesity (or preobesity) is a primary upstream risk factor for Type 2 Diabetes, contributing to more than 50% of global T2D disability-adjusted life years.Strong
- Chronic low-grade inflammation, driven by obesity and ectopic lipid deposition, impairs insulin signaling and beta-cell function through pathways like NF-κB, JNK, and oxidative stress.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →